A highly purified recombinant glycoprotein form of human THYROID-STIMULATING HORMONE, produced by recombinant DNA technology comprising two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites, and a beta subunit of 118 residues containing one N-linked glycosylation site. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.
Removal of tissue by vaporization, abrasion, or destruction. Methods used include heating tissue by hot liquids or microwave thermal heating, freezing (CRYOABLATION), chemical ablation, and photoablation with LASERS.
A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity.
Cell surface proteins that bind pituitary THYROTROPIN (also named thyroid stimulating hormone or TSH) and trigger intracellular changes of the target cells. TSH receptors are present in the nervous system and on target cells in the thyroid gland. Autoantibodies to TSH receptors are implicated in thyroid diseases such as GRAVES DISEASE and Hashimoto disease (THYROIDITIS, AUTOIMMUNE).
A highly vascularized endocrine gland consisting of two lobes joined by a thin band of tissue with one lobe on each side of the TRACHEA. It secretes THYROID HORMONES from the follicular cells and CALCITONIN from the parafollicular cells thereby regulating METABOLISM and CALCIUM level in blood, respectively.
A tripeptide that stimulates the release of THYROTROPIN and PROLACTIN. It is synthesized by the neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, TRH (was called TRF) stimulates the release of TSH and PRL from the ANTERIOR PITUITARY GLAND.

TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human bone marrow-derived mesenchymal stem cells. (1/6)

 (+info)

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. (2/6)

 (+info)

Increasing the yield of recombinant thyroid-stimulating hormone-stimulated 2-(18-fluoride)-flu-2-deoxy-D-glucose positron emission tomography-CT in patients with differentiated thyroid carcinoma. (3/6)

 (+info)

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. (4/6)

 (+info)

Unexpected symptoms after rhTSH administration due to occult thyroid carcinoma metastasis. (5/6)

(1)(8)F-fluorodeoxyglucose positron emission tomography ((1)(8)FDG-PET) scintigraphy is a useful imaging technique in the evaluation of metastasised thyroid carcinoma. Administration of recombinant human thyrotropin (rhTSH, Thyrogen(R)) increases the diagnostic yield of this procedure. Here we present a 64-year-old male who was followed for Hurthle cell carcinoma of the thyroid with several intrapulmonary metastases. He developed sudden complaints of neck pain following rhTSH administration as part of the routine preparation for a diagnostic (1)(8)FDG-PET/CT procedure. This investigation subsequently revealed a previously undetected metastatic lesion in the first cervical vertebra, with no signs of spinal cord compression. Treatment with a nonsteroidal anti-inflammatory drug reduced the symptoms sufficiently, and a few weeks later the neurosurgeon performed a complete resection of the metastasis. It is likely that the symptoms were caused by oedema and/or increased blood flow to the lesion. Physicians should be aware that rhTSH administration to patients with disseminated thyroid carcinoma may lead to sudden onset of symptoms caused by previously occult metastases.  (+info)

Recombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation. (6/6)

BACKGROUND: To prevent the unwarranted effects of post-thyroidectomy hypothyroidism prior to radiodine (RAI) ablation, patients with well-differentiated thyroid cancer can currently undergo this treatment while in a euthyroid state. This is achieved with the use of recombinant human thyroid-stimulating hormone (rhTSH) injections prior to the ablation. OBJECTIVES: To demonstrate the efficacy of rhTSH in radioiodine thyroid ablation in patients with differentiated thyroid cancer. METHODS: We conducted a retrospective study of patients who underwent total thyroidectomy for well-differentiated thyroid cancer with different levels of risk, treated with rhTSH prior to remnant ablation with radioiodine. RESULTS: Seventeen patients with thyroid cancer were studied and followed fora median of 25 months (range 8-49 months). Ablation (defined as stimulated thyroglobulin < 1 mg/ml and negative neck ultrasonography) was successful in 15 patients (88.2%). One of the patients was lost to follow-up. CONCLUSIONS: The use of rhTSH with postoperative radioiodine ablation may be an efficient tool for sufficient thyroid remnant ablation, avoiding hypothyroidal state in the management of thyroid cancer patients.  (+info)

Thyrotropin alfa is a recombinant form of human thyroid-stimulating hormone (TSH) used as a diagnostic aid in the investigation of reduced thyroid function (hypothyroidism). It is not to be confused with thyrotropin, which is the endogenous TSH produced by the pituitary gland. Thyrotropin alfa is used in tests to evaluate thyroid gland function and to help diagnose the cause of low thyroid hormone levels.

The medication is administered via subcutaneous injection, stimulating the thyroid gland to produce and release thyroid hormones T3 and T4. Blood samples are then taken at various intervals following the injection, allowing the measurement of T3 and T4 levels over time. This information can help differentiate between primary hypothyroidism (a problem with the thyroid gland itself) and secondary hypothyroidism (a problem with the pituitary gland or hypothalamus that affects TSH production).

It is important to note that thyrotropin alfa should only be used under the supervision of a healthcare professional, as inappropriate use can lead to hyperthyroidism and other related complications.

Ablation techniques are medical procedures that involve the removal or destruction of body tissue or cells. This can be done through various methods, including:

1. Radiofrequency ablation (RFA): This technique uses heat generated by radio waves to destroy targeted tissue. A thin probe is inserted into the body, and the tip of the probe emits high-frequency electrical currents that heat up and destroy the surrounding tissue.
2. Cryoablation: Also known as cryosurgery, this technique uses extreme cold to destroy abnormal tissue. A probe is inserted into the body, and a gas is passed through it to create a ball of ice that freezes and destroys the targeted tissue.
3. Microwave ablation: This technique uses microwaves to heat up and destroy targeted tissue. A probe is inserted into the body, and microwaves are emitted from the tip of the probe to heat up and destroy the surrounding tissue.
4. Laser ablation: This technique uses laser energy to vaporize and destroy targeted tissue. A laser fiber is inserted into the body, and the laser energy is directed at the targeted tissue to destroy it.
5. High-intensity focused ultrasound (HIFU): This technique uses high-frequency sound waves to heat up and destroy targeted tissue. The sound waves are focused on a specific area of the body, and the heat generated by the sound waves destroys the targeted tissue.

Ablation techniques are used in various medical fields, including cardiology, oncology, and neurology, to treat a range of conditions such as arrhythmias, cancer, and chronic pain.

Thyrotropin, also known as thyroid-stimulating hormone (TSH), is a hormone secreted by the anterior pituitary gland. Its primary function is to regulate the production and release of thyroxine (T4) and triiodothyronine (T3) hormones from the thyroid gland. Thyrotropin binds to receptors on the surface of thyroid follicular cells, stimulating the uptake of iodide and the synthesis and release of T4 and T3. The secretion of thyrotropin is controlled by the hypothalamic-pituitary-thyroid axis: thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates the release of thyrotropin, while T3 and T4 inhibit its release through a negative feedback mechanism.

Thyrotropin receptors (TSHRs) are a type of G protein-coupled receptor found on the surface of cells in the thyroid gland. They bind to thyroid-stimulating hormone (TSH), which is produced and released by the pituitary gland. When TSH binds to the TSHR, it activates a series of intracellular signaling pathways that stimulate the production and release of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). These hormones are important for regulating metabolism, growth, and development in the body. Mutations in the TSHR gene can lead to various thyroid disorders, such as hyperthyroidism or hypothyroidism.

The thyroid gland is a major endocrine gland located in the neck, anterior to the trachea and extends from the lower third of the Adams apple to the suprasternal notch. It has two lateral lobes, connected by an isthmus, and sometimes a pyramidal lobe. This gland plays a crucial role in the metabolism, growth, and development of the human body through the production of thyroid hormones (triiodothyronine/T3 and thyroxine/T4) and calcitonin. The thyroid hormones regulate body temperature, heart rate, and the production of protein, while calcitonin helps in controlling calcium levels in the blood. The function of the thyroid gland is controlled by the hypothalamus and pituitary gland through the thyroid-stimulating hormone (TSH).

Thyrotropin-Releasing Hormone (TRH) is a tripeptide hormone that is produced and released by the hypothalamus in the brain. Its main function is to regulate the release of thyroid-stimulating hormone (TSH) from the anterior pituitary gland. TRH acts on the pituitary gland to stimulate the synthesis and secretion of TSH, which then stimulates the thyroid gland to produce and release thyroid hormones (triiodothyronine (T3) and thyroxine (T4)) into the bloodstream.

TRH is a tripeptide amino acid sequence with the structure of pGlu-His-Pro-NH2, and it is synthesized as a larger precursor molecule called preprothyrotropin-releasing hormone (preproTRH) in the hypothalamus. PreproTRH undergoes post-translational processing to produce TRH, which is then stored in secretory vesicles and released into the hypophyseal portal system, where it travels to the anterior pituitary gland and binds to TRH receptors on thyrotroph cells.

In addition to its role in regulating TSH release, TRH has been shown to have other physiological functions, including modulation of feeding behavior, body temperature, and neurotransmitter release. Dysregulation of the TRH-TSH axis can lead to various thyroid disorders, such as hypothyroidism or hyperthyroidism.

No FAQ available that match "thyrotropin alfa"

No images available that match "thyrotropin alfa"